To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1 / Phase 2	2026-07-10		NCT07454187

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hangzhou Sumgen Biotech Co., Ltd.	8

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Henan Cancer Hospital	Zhengzhou	China	76
The First Affiliated Hospital of Soochow University	Suzhou	China	101
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)	Xi’an	China	2
The Second Affiliated Hospital Zhejiang University School Of Medicine	Hangzhou	China	2